GlassScriptPhysician profile
Sonya Ambriz
NPI 1336717487
$1,252.65
in general payments reported to CMS, 2019-2025
14 companies · $576 in 2025
The $576 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.25 · 2022: $168 · 2023: $223 · 2024: $261 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057 · Travel and Lodging: $4.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.50 |
| Travel and Lodging | $4.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $261.86 | 2023-2025 | Mounjaro, Zepbound |
| Fresenius USA Marketing, INC. | $227.87 | 2022-2025 | Velphoro, Velphoro |
| Ardelyx, INC. | $207.17 | 2024-2025 | Ibsrela |
| Cranial Technologies, INC | $118.62 | 2023-2025 | Doc Band |
| Akebia Therapeutics INC | $87.63 | 2021-2025 | Auryxia, Vafseo |
| Mannkind Corporation | $73.46 | 2022-2023 | Afrezza |
| Novo Nordisk INC | $56.71 | 2022 | |
| Becton, Dickinson and Company | $49.82 | 2023-2024 | Bd Onclarity |
| Astrazeneca Pharmaceuticals LP | $40.07 | 2025 | Farxiga |
| Merck Sharp & Dohme LLC | $37.60 | 2024 | Vaxelis, Vaxneuvance, Gardasil |
| Vanda Pharmaceuticals INC. | $34.00 | 2023 | Hetlioz |
| Bayer Healthcare Pharmaceuticals INC. | $20.76 | 2025 | |
| Xeris Pharmaceuticals, INC. | $20.70 | 2025 | Recorlev |
| Exeltis, USA INC. | $16.38 | 2023 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonya Ambriz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.